Abstract
Epidemiology
The interest in non-alcoholic fatty liver disease (NAFLD) arose about three decades ago, when Ludwig et al.
described liver disease not (1) sufficiently understood and not having a name. The reference group consisted of 20 patients with a histological appearance reminiscent of the alcoholic hepatitis with a potential evolution towards cirrhosis, which gave the name of the observed aspect: nonalcoholic steatohepatitis. Already then it has b e e n h i g h l i g h t e d t h a t n o n -a l c o h o l i c steatohepatitis is a condition directly related to obesity and diabetes; the most common presentation is hepatomegaly and elevations of liver enzymes.
Prevalence
NAFLD is the most common hepatic disease in industrialized Western countries, with a globally reported prevalence of 6-35%
(median 20%) . In Europe, the median (2) prevalence is 25-26% with wide variations (3) by population.
Risk factors. The importance of type II diabetes
NAFLD's major risk factors are identical to the components of the metabolic syndrome:
central obesity, type II diabetes, dyslipidemia, and insulin resistance. Currently, NAFLD is considered " " to be the hepatic de facto component of the metabolic syndrome . (4) However, the increase in NAFLD prevalence over the past decade is due to epidemiological and pathophysiological association with type II diabetes and obesity. The prevalence of NAFLD in obese and diabetic adults exceeds 70% . Also, type II diabetes and obesity are (5) 
b. Type II diabetes -a consequence of chronic liver diseases
Depending on the etiology, the degree of hepatic impairment and the diagnostic criteria, the reported incidence of glucose intolerance varies between 70-85%, and of diabetes mellitus between 40-60% . Since (13) the early stages of chronic liver disease, insulin resistance and glucose intolerance have been found in the vast majority of these patients . Diabetes mellitus is manifested as (14) liver function is deteriorating, and is 
NAFLD diagnosis
In clinical practice, NAFLD currently remains a diagnostic of exclusion, and the lack of positive diagnostic criteria is a challenge.
In practical, operational terms, the clinician must follow four steps in the NAFLD assessment. Firstly, an excess of steatose content in the liver should be identified using a series of imaging techniques (abdominal ultrasound) or, in some cases, hepatic biopsy, which remains the reference standard for diagnosis, but also a method far away from the ideal. Secondly, the clinician must exclude the alcoholic, viral, pharmacological, autoimmune or genetic cause of steatosis liver disease.
Thirdly, it is necessary to evaluate the presence of other components of the metabolic syndrome, which has already been demonstrated in the evaluation of diabetic patients. Fourthly, the severity of liver fibrosis, which is the most potent predictor of mortality in NAFLD, is evaluated . (16) The last 10 years have played a crucial role in the evaluation of hepatic fibrosis using elastographic methods . These techniques (17) use waves to stimulate hepatic tissue, 
Treatment of NAFLD associated with diabetes mellitus

Maintaining ideal body weight
Maintaining an adequate body weight plays the most important role in preventing NAFLD.
Also, the best solution for NAFLD regression already installed in overweight patients with type II diabetes is weight loss, and the safest and most effective method is through an adequate diet. In patients with NAFLD and diabetes, weight loss improved serum levels of insulin, liver function, and quality of life . In (19) recent years, pharmacological agents used to General Reviews (21) bupropion in combination . These agents are (22) a reasonable therapeutic solution for patients who cannot reach an adequate body weight by changing their lifestyle and diet.
Antidiabetic medication
Glycemic level control is the primary goal in 
Statins
In addition to the countless effects of multiple statin-class members, there is evidence that statins can also reduce liver steatosis in NAFLD . There is still no definite approval for (24) statins in the prevention and treatment of NAFLD, but further studies are needed to determine the magnitude and duration of potential effects in NAFLD in the presence and absence of type II diabetes mellitus.
The PIVENS study (25) In this study, there was significant evidence that vitamin E was superior to placebo in the treatment of non-alcoholic steatohepatitis, and pioglitazone significantly improved the patients' histological appearance. 
